PhARMA Innovation (PIF) made a strong presence at the Bio3 Forum 2025 on Biotechnology, Bioinformatics & Bioeconomy, held on September 15–19 in Athens, under the theme “Fostering Collaboration in Industry & Academia.” The Forum served as a key reference point for the international scientific and business community, bringing together leading representatives from the pharmaceutical industry, biotechnology, academic research, and innovation, with the aim of strengthening dialogue and strategic collaborations that will shape the future of health.
PIF was represented by Ms. Labrina Barmpetaki, President of PhARMA Innovation and Managing Director of AbbVie Greece, Cyprus, and Malta, as well as Mr. Ioannis Kotsiopoulos, General Manager of PIF.
Ms. Barmpetaki participated in the panel titled “Visionary Leadership in Pharma: Building the Next Healthcare Paradigm”, where she highlighted the major challenges facing the pharmaceutical industry today. As she emphasized, “the lack of predictability, doubts about the accessibility of systems, and questioning of their sustainability are three critical factors that shape the environment in which we are called to operate”. She also underlined that “the goal is to turn policies into catalysts rather than obstacles for innovation, so that patients can access the treatments they need at the right time.”
In her remarks, she focused on the role of purpose-driven leadership, stating: “A visionary leader is one who can unite people around a common purpose -and for us, that purpose is always the patient. Purpose-driven leadership can overcome obstacles, turn challenges into opportunities, and propel us forward. We do not follow, we shape. This is also the role of PIF: to contribute to public discourse, make the country more competitive, and create the conditions for sustainable development in healthcare.”
Referring to the future of the pharmaceutical industry, she emphasized that innovation is not limited to medicine but extends to services, data, and technologies. “The future lies in partnerships with technology providers, startups, and institutions. These collaborations are the ‘holy grail’ of tomorrow’s pharmaceutical industry, as only through them can we ensure effectiveness, compliance, and sustainable healthcare solutions”.
In conclusion, she highlighted the value of resilience and the need to nurture the next generation: “Leadership is a responsibility. We must empower new skills, bring fresh ideas, and give a voice to the next generation. And above all, we must remember to celebrate the small victories, because these are what lead to the big changes”.
On his part, PIF’s General Manager, Mr. Ioannis Kotsiopoulos, chaired the panel titled “The Digital Health Innovation: Patient Data as the Driver of Innovation in Biotech”. The discussion focused on the importance of structured and compatible information, the applications of data in biotechnology and digital health, as well as the necessary collaboration models that will allow innovation to grow and be sustained over time.
Through its participation in the Bio3 Forum 2025, PhARMA Innovation reaffirmed its strategic role as an institutional interlocutor in the healthcare sector. Through dialogue and collaboration with industry, the academic community, and the public sector, PIF continues to shape policy proposals that promote innovation, strengthen the healthcare system, and ensure patients’ sustainable access to the innovative therapies of tomorrow.
